Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Focus Cayman Islands.
Press releases published on May 20, 2025
Newsmatics Empowers Masaryk University Students with Cutting-Edge News Data Tools
EIN Presswire
·
May 20, 2025
Newsmatics engaged with students at Faculty Day, highlighting how AI and data science are reshaping the media industry WASHINGTON , DC, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- Newsmatics’ innovative products took center stage for students at …
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
GlobeNewswire
·
May 20, 2025
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “ …
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 20, 2025
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new Chief …
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 20, 2025
NOVATO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44 …
Segra International Acquires Klonetics to Expand Nursery Capacity and Accelerate Growth
GlobeNewswire
·
May 20, 2025
VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Segra International (“Segra”), a global leader in cannabis agriculture technology, proudly announces its strategic amalgamation with Klonetics Plant Science Inc., a licensed cannabis nursery and …
Global Alzheimer’s Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer’s Disease
GlobeNewswire
·
May 20, 2025
WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro …
TrialWire the AI and Algorithm-powered Platform Named a Fierce CRO Award Finalist in the “Outstanding Patient Recruitment and Retention” Category
GlobeNewswire
·
May 20, 2025
SAN FRANCISCO, May 20, 2025 (GLOBE NEWSWIRE) -- TrialWire today announces it was named a Fierce CRO Award finalist by Fierce Biotech in the Outstanding Patient Recruitment and Retention category. TrialWire is the AI and algorithm-powered patient- …
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
GlobeNewswire
·
May 20, 2025
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB+, with a stable outlook; from BB. Fitch's report cites …
Neuphoria Provides First Quarter 2025 Business Updates
GlobeNewswire
·
May 20, 2025
Cash runway into Q3 2026 AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025 α7 nicotinic acetylcholine receptor PAM MK-1167 partnered with Merck and in Phase 2 clinical trial in Alzheimer’s …
GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l’approbation du prix et du remboursement d’Iqirvo® par Ipsen en Italie
GlobeNewswire
·
May 20, 2025
Lille (France), Cambridge (Massachusetts, Etats-Unis), Zurich (Suisse), le 20 mai, 2025 – GENFIT (Nasdaq et Euronext : GNFT), société́ biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares …
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
GlobeNewswire
·
May 20, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today …
RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum
GlobeNewswire
·
May 20, 2025
ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate …
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
GlobeNewswire
·
May 20, 2025
SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane …
INVO Fertility Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 20, 2025
SARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and …
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with…
GlobeNewswire
·
May 20, 2025
REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development …
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
GlobeNewswire
·
May 20, 2025
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers …
Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025
GlobeNewswire
·
May 20, 2025
Topline results for AP02 (inhaled nintedanib) confirmed safety and tolerability with limited systemic exposure and substantially improved lung exposure compared to oral nintedanib AP01 (inhaled pirfenidone) treatment demonstrated long-term antifibrotic …
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
GlobeNewswire
·
May 20, 2025
Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant …
Alameda Health System expands stroke care with Wilma Chan Highland Hospital Campus’ new certification
GlobeNewswire
·
May 20, 2025
OAKLAND, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Alameda Health System (AHS) patients experiencing the sudden and frightening symptoms of a stroke will now receive faster and more-integrated care, thanks to the Wilma Chan Highland Hospital Campus’ (WCHHC) …
Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight
GlobeNewswire
·
May 20, 2025
New York, USA, May 20, 2025 (GLOBE NEWSWIRE) -- Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight The moderate to severe atopic dermatitis market is experiencing strong growth driven by rising …